From the Journals

Efficacy and Safety of 8 mg Aflibercept in PULSAR Extension

Patients who switched from 2 mg to 8 mg maintained their vision and extended time between treatments with no vasculitis or other retinal occlusive events.

Share

  • 1

    PULSAR extension trial evaluated 8 mg aflibercept vs. the conventional 2 mg dose in neovascular AMD.

  • 2

    Patients who switched to 8 mg maintained vision and extended treatment intervals.

  • 3

    No safety concerns, such as vasculitis or retinal occlusive events, were reported over 3 years.

  • 4

    High-dose aflibercept demonstrated benefits for neovascular AMD treatment up to 3 years.

  • 5

    Study provides insights for clinical practice and potential treatment strategies.

Original Source(s)

Efficacy and Safety of 8 mg Aflibercept in PULSAR Extension

Patients who switched from 2 mg to 8 mg maintained their vision and extended time between treatments with no vasculitis or other retinal occlusive events.

  • by Tien Wong, MD, PhD, Michael A. Singer, MD

  • January 1, 2025

  • 6 min

Related Content

Metformin and AMD: Signal or Noise?

Five-year population study details 37% lower incidence of intermediate AMD in type 2 diabetic patients prescribed metformin

Understanding Protocol AO, the DRCR Retina Network’s Study of Home OCT

A conversation with Christina Y. Weng, MD, MBA

Coding Q&A: Coding Guidelines for Wet AMD

Proper use of ICD-10-CM codes ensures compliance and prompt payment.